JanOne Inc. Stock Price, News & Analysis

JanOne Inc. (Nasdaq: JAN) announced a strategic review process for its legacy businesses, particularly its recycling segment. This initiative follows interest from potential buyers. CEO Tony Isaac emphasized the focus on advancing their lead candidate, JAN101, for treating peripheral artery disease (PAD) and related complications from Covid-19. The company aims to maximize shareholder value through these transactions, although no guarantees on successful negotiations or terms have been established. JAN101 has shown positive results in trials, with further studies expected in early 2021.

JanOne Inc. (NASDAQ: JAN) has confirmed the stability of its developmental batch of JAN101, a treatment for peripheral artery disease (PAD). The company is set to commence GMP production to support Phase 2b trials slated for early 2021. Additionally, JanOne is finalizing an IND application for JAN101 aimed at treating Covid-19 vascular complications. The partnership with Eurofins CDMO ensures the integrity of clinical trial batches. Both clinical trials for PAD and potential Covid-19 treatment are crucial for the company’s future growth and market presence.

JanOne Inc. (Nasdaq: JAN) has selected a leading bottling and labeling partner for its investigational drug, JAN101, aimed at treating vascular complications from Covid-19 and Peripheral Artery Disease (PAD). The IND application for JAN101 is expected to be submitted to the FDA soon, with Phase 2b trials for PAD scheduled to start in early 2021. The sodium nitrite-based JAN101 demonstrated promising results in earlier studies, showing potential to improve blood flow and reduce inflammation. The company's strategy focuses on prioritizing GMP manufacturing to ensure timely clinical product availability.

JanOne Inc. (Nasdaq: JAN) has completed its initial engineering batch of JAN101, a proprietary sodium nitrite compound aimed at treating Peripheral Artery Disease (PAD) and potential Covid-19 vascular complications. Following positive Phase 1 and 2a trial results, the company plans to submit an investigational new drug application for Covid-19 treatments soon. JanOne anticipates starting Phase 2b trials for PAD in early 2021 and expects to deliver 250,000 doses within 30 days of production start, scaling up to 20 million doses by next year.

JanOne Inc. (Nasdaq: JAN) announced a teleconference on August 25, 2020, at 4:15 PM ET to discuss updates on its lead drug candidate, JAN101. JAN101 targets peripheral artery disease (PAD) and may help with COVID-19 vascular complications. The drug has shown positive results in Phase 1 and 2a trials, with a pivotal Phase 2b study planned for early 2021. The global PAD market is projected to grow from $36.1 billion in 2017 to $52.0 billion by 2022. The company is also preparing an IND package for FDA submission to explore COVID-19 treatment applications.

JanOne Inc. (Nasdaq: JAN) announced its participation in the 12th Annual LD 500 Conference on September 3, 2020, at 3:00 PM ET. Dr. Tony Giordano, Chief Scientific Officer, will present virtually. The company has partnered with CATO SMS to expand its FDA authorized Investigational New Drug (IND) for JAN101, aimed at treating vascular complications in COVID-19 patients. Phase 2b trials for JAN101, an oral sodium nitrite formulation, are expected to start in early 2021. For more details, visit JanOne's investor and scientific presentations linked in the release.

JanOne (NASDAQ: JAN) has successfully finished formulating **JAN101**, a potential treatment for **Peripheral Artery Disease (PAD)**, and is preparing for **Phase 2b trials**. The IND submission for treating **COVID-19 vascular complications** is also expected by late August 2020. The company is set to manufacture an initial batch of **250,000 doses** by mid-September 2020 and aims for commercial production to support trials in early 2021. The strategic purchase of **1,000 kilos of sodium nitrite** is also underway to ensure sufficient supply for over **20 million doses**.

JanOne (NASDAQ: JAN) announced a collaboration with CATO SMS, a prominent clinical contract research organization, to enhance the development of JAN101. This investigational drug, aimed at treating vascular complications in COVID-19 patients, is set to enter Phase 2b trials in early 2021. Previous studies suggest JAN101 may restore endothelial cell function, potentially improving oxygen delivery to vital organs. The company plans to submit an IND application to the FDA soon and aims for emergency use authorization for COVID-19 patients.